Close Menu

NEW YORK – Envisagenics announced Tuesday it has entered into a research program agreement with Johnson & Johnson's Lung Cancer Initiative (LCI.)

Under the terms of the agreement, Envisagenics will build predictive models for lung cancer progression and risk and use its SpliceCore software platform to analyze LCI's data. 

Financial and other details were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.